[HTML][HTML] Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
JH Leung, Y Tai, SY Wang, HTY Fion, H Tsung-Chin… - The Breast, 2022 - Elsevier
Background The rising cost of cancer drug therapy threatens the long-term sustainability of
Taiwan National Health Insurance. Cost savings can be achieved through various …
Taiwan National Health Insurance. Cost savings can be achieved through various …
Assessment of the cost-effectiveness of HER2-targeted treatment pathways in the neoadjuvant treatment of high-risk HER2-positive early-stage breast cancer
Introduction This study aims to assess differences in costs and benefits of treatment
strategies for high-risk human epidermal growth factor receptor 2 positive (HER2+) early …
strategies for high-risk human epidermal growth factor receptor 2 positive (HER2+) early …
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer
A McBride, K MacDonald… - Journal of Medical …, 2021 - Taylor & Francis
Aims To investigate the cost-efficiency and budget-neutral expanded access of biosimilar
intravenous trastuzumab-dkst versus reference intravenous (trastuzumab-IV) and …
intravenous trastuzumab-dkst versus reference intravenous (trastuzumab-IV) and …
Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA
S Ailawadhi, A Ravelo, CD Ng, B Shah… - Journal of …, 2024 - becarispublishing.com
Aim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a
growing population of CLL survivors; these patients have a higher risk of developing second …
growing population of CLL survivors; these patients have a higher risk of developing second …
[HTML][HTML] Health care resource utilization and costs for metastatic breast cancer patients newly treated with human epidermal growth factor receptor 2 (HER2)-targeted …
R Mahtani, N Oestreicher, D Lalla, A Ogbonnaya… - Clinical breast …, 2022 - Elsevier
Introduction: HER2-positive metastatic breast cancer (mBC) is an incurable disease
associated with years of chronic therapy and excess cost. HER2-targeted therapies have …
associated with years of chronic therapy and excess cost. HER2-targeted therapies have …
Economic burden of central nervous system metastases in human epidermal growth factor receptor 2–positive breast cancer
NRM Schwartz, K DeBusk, A Forero-Torres… - Future …, 2021 - Taylor & Francis
Aim: Compare healthcare resource utilization and costs among patients with HER2+
metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases …
metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases …
[HTML][HTML] An evaluation of the healthcare costs of metastatic breast cancer: a retrospective matched cohort study
HM Chen, JH Chen, SC Chiang, YC Lin, Y Ko - Medicine, 2021 - journals.lww.com
To determine the economic burden of metastatic breast cancer (MBC) in Taiwan, we
conducted a national retrospective claim database analysis to evaluate the incremental …
conducted a national retrospective claim database analysis to evaluate the incremental …
ORLNC1 Suppresses Cell Growth in HER2-Positive Breast Cancer via miRNA-296 Sponging
X Cheng, Z Huang, A Pan… - Current Molecular …, 2023 - ingentaconnect.com
Background: Accumulating research has demonstrated that aberrant levels of long
noncoding RNAs (LncRNAs) are related to cancer progression. The effects of ORLNC1 in …
noncoding RNAs (LncRNAs) are related to cancer progression. The effects of ORLNC1 in …
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer–a Danish register-based study from 2005 to 2016
M Spanggaard, J Olsen, KF Jensen… - BMC Health Services …, 2022 - Springer
Background Information and knowledge about cost of illness and labour productivity in
patients with HER2-positive early-stage and metastatic breast cancer treated with …
patients with HER2-positive early-stage and metastatic breast cancer treated with …
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
JJ Carlson, GF Guzauskas, RA Dann… - Journal of Medical …, 2021 - Taylor & Francis
Abstract Background DiviTum TKa, a blood-based biomarker assay developed to monitor
and predict treatment response in hormone receptor positive metastatic breast cancer (HR+ …
and predict treatment response in hormone receptor positive metastatic breast cancer (HR+ …